Filing Flows › Caribou Biosciences (CRBU) › Guidance & outlook
Caribou Biosciences (CRBU) guidance and outlook
Caribou Biosciences' 10-Q filed Nov 5, 2026 makes 7 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- We also intend to terminate applicable contracts, resolve various intellectual property licensing agreements, and seek ways to sublease our facilities or terminate facility leases.
- We have not set a timeline for the completion of our review of strategic alternatives, and we do not intend to provide further updates unless and until our Board has approved a course of action, the review process is concluded, or disclosure is otherwise determined to be appropriate or required.
- We have not generated any revenue from product sales, and, following the planned discontinuation of our vispa-cel and CB-011 CAR-T cell therapy programs, we do not expect to generate revenue from sales of any product candidates.
- Following our announced 2026 Restructuring, we expect to incur certain expenses related to one-time severance payments, continued healthcare coverage, costs to wind down the ANTLER phase 1 clinical trial and CaMMouflage phase 1 clinical trial, and costs associated with the anticipated sublease or termination of our facility leases.
- We have not generated any revenue from product sales to date and do not expect to generate any revenue from the sale of products in the foreseeable future.
- However, payments made prior to the receipt of goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses and other current assets in our unaudited condensed consolidated balance sheets.
- We have no current ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over the next five years, except for our lease commitments and payments under certain of our license agreements as described in Notes 4 and 8 to our unaudited condensed consolidated financial statements included elsewhere in this Form 10-Q.
Caribou Biosciences' latest quarter
Caribou Biosciences, Q3 2026: revenue $1.6M (-27% year over year), net loss $26.6M, operating cash flow −$22.5M. The chart follows the revenue to costs, profit and cash.
Questions
What does Caribou Biosciences expect?
We also intend to terminate applicable contracts, resolve various intellectual property licensing agreements, and seek ways to sublease our facilities or terminate facility leases. We have not set a timeline for the completion of our review of strategic alternatives, and we do not intend to provide further updates unless and until our Board has approved a course of action, the review process is concluded, or disclosure is otherwise determined to be appropriate or required. We have not generated any revenue from product sales, and, following the planned discontinuation of our vispa-cel and CB-0
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.